The New England journal of medicine
-
Editorial Comment
Adjuvant Nivolumab in Esophageal Cancer - A New Standard of Care.
-
Randomized Controlled Trial Multicenter Study
Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone morphogenetic protein pathway signaling is associated with both hereditary and idiopathic subtypes. Sotatercept, a novel fusion protein, binds activins and growth differentiation factors in the attempt to restore balance between growth-promoting and growth-inhibiting signaling pathways. ⋯ Treatment with sotatercept resulted in a reduction in pulmonary vascular resistance in patients receiving background therapy for pulmonary arterial hypertension. (Funded by Acceleron Pharma; PULSAR ClinicalTrials.gov number, NCT03496207.).